Evidence map›Paper›PMID 29661164›Full record

ArticleBMC cancer2018

Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).

Ludovic Dhont, Melania Pintilie, Ethan Kaufman, Roya Navab, Shirley Tam, Arsène Burny, Frances Shepherd, Alexandra Belayew, Ming-Sound Tsao, Céline Mascaux

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Multi-omics analysis of HLTF context-dependent regulation across TCGA cohorts revealed its potential as new biomarker in tumour.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ludovic DhontLaboratory of Molecular Biology, Research Institute for Health Sciences and Technology, Université de Mons, Mons, Belgium.
Melania PintilieBiostatistics Department, University of Toronto, Toronto, Canada.
Ethan KaufmanPrincess Margaret Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Roya NavabPrincess Margaret Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Shirley TamPrincess Margaret Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Arsène BurnyUniversité Libre de Bruxelles (ULB), Bruxelles, Belgium.
Frances ShepherdDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Alexandra BelayewLaboratory of Molecular Biology, Research Institute for Health Sciences and Technology, Université de Mons, Mons, Belgium.
Ming-Sound TsaoPrincess Margaret Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Céline MascauxDepartment of Muldisciplinary Oncology and Therapeutic Innovations, Assistance Publique des Hôpitaux de Marseille (AP-HM), Aix-Marseille University, Chemin des Bourrely, 13195, Marseille, Cedex 20, France. celinejmmascaux@gmail.com.

Funding

Canadian Cancer Society 701595
6 · The paper itself

Abstract

backgroundThe relapse rate in early stage non-small cell lung cancer (NSCLC) after surgical resection is high. Prognostic biomarkers may help identify patients who may benefit from additional therapy. The Helicase-like Transcription Factor (HLTF) is a tumor suppressor, altered in cancer either by gene hypermethylation or mRNA alternative splicing. This study assessed the expression and the clinical relevance of wild-type (WT) and variant forms of HLTF RNAs in NSCLC.

methodsWe analyzed online databases (TCGA, COSMIC) for HLTF alterations in NSCLC and assessed WT and spliced HLTF mRNAs expression by RT-ddPCR in 39 lung cancer cell lines and 171 patients with resected stage I-II NSCLC.

resultsIn silico analyses identified HLTF gene alterations more frequently in lung squamous cell carcinoma than in adenocarcinoma. In cell lines and in patients, WT and I21R HLTF mRNAs were detected, but the latter at lower level. The subgroup of 25 patients presenting a combined low WT HLTF expression and a high I21R HLTF expression had a significantly worse disease-free survival than the other 146 patients in univariate (HR 1.96, CI 1.17-3.30; p = 0.011) and multivariate analyses (HR 1.98, CI 1.15-3.40; p = 0.014).

conclusionA low WT HLTF expression with a high I21R HLTF expression is associated with a poor DFS.

Indexed as

AdultAgedAlternative SplicingBiomarkers, TumorCarcinoma, Non-Small-Cell LungDisease-Free SurvivalDNA-Binding ProteinsDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansMaleNeoplasm Recurrence, LocalNeoplasm StagingPrognosisTranscription FactorsBiomarkers, TumorDNA-Binding ProteinsHLTF protein, humanTranscription FactorsAlternative splicingHLTFNon-small cell lung cancerPrognosis

Identifiers

PMID29661164
PMCPMC5902896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.